Temporary and voluntary hold on manufacturing and release of Ventolin® Solution for Intravenous Infusion 5mg/5ml (salbutamol sulphate) at its manufacturing site

GSK would like to inform healthcare professionals of a temporarily and voluntary hold on manufacturing and release of Ventolin®Solution for Intravenous Infusion 5mg/5ml (salbutamol sulphate) at its Parma manufacturing site. This was a precautionary measure while GSK investigated and resolved an issue with data inconsistencies at this facility. There are no concerns over the quality of products already distributed or those held locally at warehouses. Healthcare providers are advised to consider alternative treatments if necessary, for patients who currently use this product. To ensure sufficient supply is available for patients currently being treated with Ventolin® Solution for Intravenous Infusion, GSK recommends healthcare professionals consider not initiating treatment in new patients until supplies return to normal. Please refer to the Dear Healthcare Professional Letter (DHCPL) for more details.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.